Zoetis Inc. (ETR:ZOE)
| Market Cap | 45.76B |
| Revenue (ttm) | 8.01B |
| Net Income (ttm) | 2.26B |
| Shares Out | n/a |
| EPS (ttm) | 5.06 |
| PE Ratio | 20.25 |
| Forward PE | 18.15 |
| Dividend | 1.78 (1.73%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 642 |
| Average Volume | 763 |
| Open | 103.90 |
| Previous Close | 104.00 |
| Day's Range | 102.94 - 104.42 |
| 52-Week Range | 102.94 - 172.60 |
| Beta | 0.96 |
| RSI | 17.98 |
| Earnings Date | Nov 4, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Full Company ProfileFinancial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
Zoetis Inc. trades at low valuations despite strong growth and pipeline. Click for my updated look at ZTS stock prospects following its Q3 earnings release.
Diamond Hill Capital's Strategic Moves: A Closer Look at Zoetis Inc.
Diamond Hill Capital's Strategic Moves: A Closer Look at Zoetis Inc.
JP Morgan Lowers Price Target for Zoetis (ZTS) to $200, Maintains Overweight Rating | ZTS Stock News
JP Morgan Lowers Price Target for Zoetis (ZTS) to $200, Maintains Overweight Rating | ZTS Stock News
I Used an AI Food Scanner App for 6 Weeks. This Is What It Taught Me About Carbs
The Zoe AI Meal Tracker app features barcode scanning, AI-powered food logging and a processed food risk scale to support healthy eating.
Decoding Zoetis Inc (ZTS): A Strategic SWOT Insight
Decoding Zoetis Inc (ZTS): A Strategic SWOT Insight
Zoetis (ZTS) Reports Strong Q3 2025 Revenue Growth
Zoetis (ZTS) Reports Strong Q3 2025 Revenue Growth
Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
Zoetis Inc. (ZTS) Q3 2025 Earnings Call November 4, 2025 8:30 AM ESTCompany ParticipantsSteven Frank - Vice President of Investor RelationsKristin Peck -...
Zoetis Inc (ZTS) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Competitive Pressures
Zoetis Inc (ZTS) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Competitive Pressures
Q3 2025 Zoetis Inc Earnings Call Transcript
Q3 2025 Zoetis Inc Earnings Call Transcript
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Animal health firm Zoetis Inc. (NYSE: ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70 . The company beat the consensus of $1.62. Adjusted net income was $754 millio...
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70.
Zoetis: No Longer A Growth Stock
Zoetis is Now Oversold (ZTS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
Zoetis (ZTS) Shares Experience Significant Decline
Zoetis (ZTS) Shares Experience Significant Decline
S&P 500 Movers: ZTS, HSIC
In early trading on Tuesday, shares of Henry Schein topped the list of the day's best performing components of the S&P 500 index, trading up 11.6%. Year to date, Henry Schein registers a 4.3% gain. An...
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima...
Zoetis down after guidance cut on macro trends
Zoetis (ZTS) stock falls and its peer Elanco (ELAN) also decline as the company cuts its 2025 outlook amid macro and operational challenges. Read more here.
Zoetis Inc. 2025 Q3 - Results - Earnings Call Presentation
This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.
Zoetis slashes its full-year outlook.
Zoetis (ZTS) Revises 2025 Revenue Forecast Amid Macro Trends
Zoetis (ZTS) Revises 2025 Revenue Forecast Amid Macro Trends
Zoetis (ZTS) Records Q3 Revenue Slightly Below Projections, Achieves Key Milestones
Zoetis (ZTS) Records Q3 Revenue Slightly Below Projections, Achieves Key Milestones
Zoetis Stock Crumbles After Slashing 2025 Sales Outlook
The animal health company now expects just $9.4 billion-$9.475 billion in sales for the year. Zoetis stock tumbled.
Zoetis (ZTS) Surpasses Q3 Earnings Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +4.94% and -0.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?